Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1551 - 1600 of 1864 results
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
- Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
- Development of XPA067.06, a potent high affinity human anti-gastrin monoclonal antibody.
- Recombinant human IL-24 suppresses lung carcinoma cell growth via induction of cell apoptosis and inhibition of tumor angiogenesis.
- Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in reconstituted SCID mice.
- Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts.
- OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.
- Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
- In vivo colocalization of antigen and cytidyl guanosyl within dendritic cells is associated with the efficacy of cancer immunotherapy.
- The humoral immune system has a key prognostic impact in node-negative breast cancer.
- Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.
- Osteopontin and Interleukin-8 Expression is Independently Associated with Prostate Cancer Recurrence.
- Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer.
- Vaccination with a Recombinant Saccharomyces cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses.
- Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents.
- Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
- Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.
- A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
- Topotecan enhances immune clearance of gliomas.
- Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
- Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model.
- Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.
- Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects.
- An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.
- Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
- Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
- Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients.
- Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
- Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice.
- Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
- Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
- Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect.
- Adenovirus-mediated HCCS1 overexpression elicits a potent antitumor efficacy on human colorectal cancer and hepatoma cells both in vitro and in vivo.
- Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells.
- Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
- Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer.
- Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
- A Multicenter Prospective Phase II Randomized Study of Extracorporeal Photopheresis for Treatment of Chronic Graft-versus-Host Disease.
- Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands.
- DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire.
- Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells.
- A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells.
- Transforming Growth Factor {beta} Engages TACE and ErbB3 to Activate PI3K/Akt in ErbB2-overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab.
- A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration.
- Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients.
- Interferon-alpha restitutes the chemosensitivity in pancreatic cancer.
- Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients.
- Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.
- Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.